微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 61.65% | -2.41% | 8.8% | 44/158 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 56.66% | -6.5% | -7.73% | 62/158 | 51.8% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 61.41% | -1.74% | -0.36% | 48/158 | 22.73% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 61.63% | -2.89% | -2.44% | 48/158 | 33.18% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 63.17% | -2.84% | 4.24% | 42/158 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 60.6% | 4.11% | -3.02% | 51/158 | 51.38% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 62.49% | 8.57% | -1.53% | 47/158 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 63.46% | 10.32% | -2.39% | 49/158 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 65.02% | 2.12% | 11.69% | 40/158 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 58.21% | 16.14% | 1.13% | 62/158 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 57.56% | 12.84% | 0.06% | 63/158 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 57.53% | 14.01% | -9.64% | 66/158 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 63.67% | 55.12% | 27.02% | 47/158 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 50.12% | -8.58% | -1.75% | 85/158 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 51.01% | 27.34% | 1.1% | 71/158 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 50.46% | -9.68% | -7.97% | 78/158 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2020-12-31 | 54.82% | 28.93% | -1.86% | 71/158 | -145.9% | 艾力斯 | 99.4% | 行业排名> |
| 2020-06-30 | 55.86% | 32.43% | 31.38% | 61/158 | 54.11% | 首药控股 | 99.94% | 行业排名> |
| 2019-12-31 | 42.52% | -5.01% | 6.14% | 93/158 | -1222.98% | 泽璟制药 | 99.96% | 行业排名> |
| 2019-09-30 | 40.06% | 2% | -5.04% | 78/158 | 55.21% | 微芯生物 | 95.14% | 行业排名> |
| 2019-06-30 | 42.19% | 2% | 2.78% | 77/158 | 55.21% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-03-31 | 41.04% | 2% | -8.31% | 73/158 | 51.05% | 微芯生物 | 95.81% | 行业排名> |
| 2018-12-31 | 44.76% | 2% | 2% | 80/158 | -208.09% | 微芯生物 | 96.09% | 行业排名> |